Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment

Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment

Background: Ticagrelor is a first-line drug for the treatment of acute ST elevation myocardial infarction (STEMI). However, approximately 20% STEMI patients taking ticagrelor exhibited a delayed response and the mechanism was still unclear. Methods: To explore the mechanism of the poor response of t...

Full description

Bibliographic Details
Main Authors:	Xi Zhang, Xiaolin Zhang, Fangnian Tong, Yi Cai, Yujie Zhang, Haixu Song, Xiaoxiang Tian, Chenghui Yan, Yaling Han
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2022-03-01
Series:	eLife
Subjects:	gut microbiota ticagrelor coronary heart disease high platelet reactivity
Online Access:	https://elifesciences.org/articles/70240

Similar Items

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
by: Piotr Adamski, et al.
Published: (2022-02-01)

Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study
by: Giuseppe Gargiulo, et al.
Published: (2024-02-01)

Efficacy and safety of cangrelor as compared to ticagrelor in patients with ST-elevated myocardial infarction (STEMI): a systematic review and meta-analysis
by: Subhro Chakraborty, et al.
Published: (2024-04-01)

Clinical outcomes with the use of ticagrelor or clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction – A prospective observational study
by: Bibek Agarwal, et al.
Published: (2022-01-01)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
by: Thomas W. Johnson, et al.
Published: (2020-12-01)

The effect of ticagrelor and clopidogrel on angiographic parameters according to diabetic status in patients with ST elevation myocardial infarction
by: F. Aydınyılmaz, et al.
Published: (2022-09-01)

The Effect of Platelet Activity, ABCB1 Genetic Polymorphism, and Renal Function on the Development of Ticagrelor-Related Dyspnea in Patients with Acute Coronary Syndrome
by: Tamakauskas V, et al.
Published: (2024-01-01)

Reversal of Platelet Inhibition in Patients Receiving Ticagrelor
by: Piotr Adamski, et al.
Published: (2022-09-01)

Ticagrelor versus clopidogrel in the management of acute myocardial infarction
by: Candice Volney, et al.
Published: (2019-07-01)

Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study)
by: Meijiao He, et al.
Published: (2022-11-01)

Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane
by: Vahideh Rabani, et al.
Published: (2018-10-01)

Ticagrelor regulates the differentiation of MDSCs after acute myocardial infarction to reduce cardiac injury
by: Zijian Huang, et al.
Published: (2024-03-01)

INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION
by: E. V. Tavlueva, et al.
Published: (2017-11-01)

Factors Determining Ticagrelor-Induced Dyspnea in Patients with Acute Coronary Syndrome
by: Vytenis Tamakauskas, et al.
Published: (2022-10-01)

Analysis of ticagrelor’s cardio-protective effects on patients with ST-segment elevation acute coronary syndrome accompanied with diabetes
by: Li Dong-Tao, et al.
Published: (2019-02-01)

Influence of Antiplatelet Agents on the Lipid Composition of Platelet Plasma Membrane: A Lipidomics Approach with Ticagrelor and Its Active Metabolite
by: Jennifer Lagoutte-Renosi, et al.
Published: (2021-01-01)

Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial
by: Dorian Garin, et al.
Published: (2024-04-01)

Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis
by: Matteo Vercellino, et al.
Published: (2017-04-01)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
by: Lulu Dai, et al.
Published: (2022-06-01)

Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change?
by: O. V. Averkov, et al.
Published: (2018-09-01)

Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy
by: Barry W. Hennigan, et al.
Published: (2022-01-01)

Ticagrelor versus clopidogrel for recurrent myocardial infarction: An outcomes-based agreement
by: Samuel K. Peasah, et al.
Published: (2023-12-01)

Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis
by: Gerhard Selhorst, et al.
Published: (2019-04-01)

The protective effect of ticagrelor on renal function in a mouse model of sepsis-induced acute kidney injury
by: Xiuhua Li, et al.
Published: (2019-02-01)

Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR)
by: Jing Shi, et al.
Published: (2021-01-01)

Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study
by: Bernadeta Chyrchel, et al.
Published: (2022-11-01)

Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013
by: O. V. Averkov
Published: (2013-02-01)

Temporal Trends of Bleeding Episodes during Half- vs. Standard-Dose Ticagrelor in Acute Coronary Syndrome Patients with Low Platelet Reactivity: A Randomized BLEEDING-ACS Trial
by: Laeun Kim, et al.
Published: (2021-03-01)

Bivalirudin vs. heparin on a background of ticagrelor and aspirin in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A multicenter prospective cohort study
by: Xiao-Fan Yu, et al.
Published: (2022-10-01)

Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake
by: Kok Weng Ow, et al.
Published: (2020-10-01)

Impact of renal function on Ticagrelor-induced antiplatelet effects in coronary artery disease patients
by: Manuel Veas Porlán, et al.
Published: (2023-06-01)

Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease
by: Meijiao He, et al.
Published: (2019-08-01)

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
by: Sukhdeep S. Basra, et al.
Published: (2018-06-01)

Assessment of myocardial salvage in patients with STEMI undergoing thrombolysis: ticagrelor versus clopidogrel
by: Stylianos Petousis, et al.
Published: (2022-07-01)

The Role of Ticagrelor in STEMI Fibrinolytic and Its Rationale to Utilize for Indonesian Patients
by: Daniel Tobing, et al.
Published: (2019-09-01)

Ticagrelor Resistance in Cardiovascular Disease and Ischemic Stroke
by: Song He, et al.
Published: (2023-02-01)

Does the level of myocardial injury differ in primary angioplasty patients loaded first with clopidogrel and the ones with ticagrelor?
by: Nil Ozyuncu, et al.
Published: (2020-07-01)

Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study
by: Jaouad Azzahhafi, et al.
Published: (2022-12-01)

Association of ADP-Induced Whole-Blood Platelet Aggregation with Serum Low-Density Lipoprotein Cholesterol in Patients with Coronary Artery Disease When Receiving Maintenance Ticagrelor-Based Dual Antiplatelet Therapy
by: Bernadeta Chyrchel, et al.
Published: (2023-07-01)